Direct-to-consumer advertising (DTCA) of drugs has been suggested to be a factor in the increased burden of healthcare spending within the US. This review article analyses the pharmaceutical spending differences between the US and New Zealand, two nations that allow DTCA. The pharmaceutical spending burden of New Zealand and the US was compared by assessing the impact of heavily advertised drugs and their position and rank in the pharmaceutical spending of their respective nation. The US spends far more money on pharmaceuticals than New Zealand. It may appear that heavily advertised drugs in the US have a potentially larger impact on what is being prescribed and paid for. It is also probable that the differences in healthcare systems in each nation (free market vs socialized medicine) can have an influence on pharmaceutical spending. The great amount of money being spent on pharmaceuticals per capita in the US is a more complex issue than can be solved solely by targeting DTCA.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/BF03256125 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Projections of Public Spending on Pharmaceuticals: A Review of Methods.
Pharmacoeconomics
January 2025
Belgian Health Care Knowledge Centre, Brussels, Belgium.
Background: Forecasting future public pharmaceutical expenditure is a challenge for healthcare payers, particularly owing to the unpredictability of new market introductions and their economic impact. No best-practice forecasting methods have been established so far. The literature distinguishes between the top-down approach, based on historical trends, and the bottom-up approach, using a combination of historical and horizon scanning data.
View Article and Find Full Text PDFEGb761 Trials for Mild-to-Moderate Dementia-What Have We Learned in the Past 18 years?
Am J Ther
January 2025
Faculty of Medicine, "Transilvania" University, Brasov, Romania; and.
Background: Dementia leads to cognitive decline affecting memory, thinking, and behavior. Current pharmaceutical treatments are symptomatic, with limited efficacy and significant drawbacks. Ginkgo biloba extract (EGb761) is being explored as an adjuvant therapy for dementia because of its potential neuroprotective effects.
View Article and Find Full Text PDFA Pilot Randomized Controlled Trial to Examine the Impact of a Therapy Dog Intervention on Loneliness in Hospitalized Older Adults.
Innov Aging
September 2024
Department of Clinical Sciences, Center for Animals and Public Policy, Cummings School of Veterinary Medicine, Tufts University, North Grafton, Massachusetts, USA.
Background And Objectives: Loneliness is linked to significant health threats and is potentially more dangerous than obesity; it affects as many as 29% of noninstitutionalized older adults. Loneliness is exacerbated for those who require inpatient rehabilitation, are displaced from their social networks, spend little time receiving therapy, and are physically inactive and socially isolated. Emerging evidence suggests that companion animals provide a number of health and well-being benefits and that interacting with a trained therapy dog may reduce loneliness.
View Article and Find Full Text PDFUse of Clinical Trial Characteristics to Estimate Costs of New Drug Development.
JAMA Netw Open
January 2025
RAND, Santa Monica, California.
Article Synopsis
- Estimates indicate significant variation in R&D costs, with 20 large firms comprising 80.8% of patient-months and showing lower costs per patient-month compared to smaller firms.
- A novel methodology was used to analyze R&D costs per drug, focusing on discrete units of activity related to clinical trials and using data from 268 US publicly traded drug developers.
- The study found that R&D costs per new drug averaged around $1.31 billion, with a lower median cost of $708 million, highlighting a skewed distribution of expenses related to drug development.
Exploring pet owners' attitudes toward compounded and human approved medicines: a questionnaire based pilot study.
Vet Res Commun
January 2025
Department of Pharmacology and Toxicology, Faculty of Medicine, University of Novi Sad, Hajduk Veljkova 3, 21000, Novi Sad, Serbia.
With the growing global pet population and increased spending on veterinary care, compounded medications offer customized, often more suitable and affordable treatment options compared to the limited available veterinary medications. This research aims to understand pet owners' attitudes towards compounded medications, focusing on their challenges and needs. A total of 300 respondents from the territory of Novi Sad, province of Vojvodina, Republic of Serbia completed the questionnaire, through face-to-face interviews at veterinary clinics.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!